Review of Systems Before Initiating Hormone Replacement Therapy
Before initiating HRT, perform a focused clinical assessment including measurement of weight, blood pressure, gynecologic examination with breast palpation, and screening for cardiovascular risk factors, VTE history, undiagnosed vaginal bleeding, and personal/family history of breast cancer. 1, 2
Essential Pre-Treatment Evaluation
Mandatory Clinical Assessment
- Cardiovascular screening: Blood pressure measurement and assessment of cardiovascular risk factors are essential 1
- Breast evaluation: Clinical breast examination and mammography (particularly important as estrogen can promote growth of subclinical breast cancer) 1, 3
- Gynecologic examination: To exclude undiagnosed abnormal vaginal bleeding, suspected or active endometrial cancer 1
- Weight and BMI: Document baseline, as BMI >30 kg/m² influences route selection 4, 1
Critical History Elements
Absolute contraindications to identify:
- Personal history of breast cancer 1, 2
- Undiagnosed abnormal vaginal bleeding 1
- Active or suspected endometrial cancer 1
- History of VTE or thrombophilia (requires hematology consultation before considering transdermal HRT) 4, 1
Conditions requiring route/regimen modification (NOT contraindications):
- Migraine with aura: Use transdermal estradiol preferentially 4
- Hypertension: Use transdermal estradiol 4, 2
- Obesity (BMI >30): Use transdermal estradiol 4, 1
- Endometriosis: Can use HRT but combined estrogen/progestogen preferred to reduce reactivation risk 4, 2
- Fibromas: Not a contraindication 4
Laboratory and Imaging
No routine laboratory monitoring is required before initiating HRT in most women 1, 2. However, specific testing should be prompted by clinical concerns:
- Bone density (DEXA): Consider 1-2 years after surgical menopause if additional risk factors for osteoporosis exist, NOT routinely before starting 1
- Lipid profile and inflammatory markers: Only if cardiovascular risk assessment indicates 5
- Hormone levels (FSH, estradiol): Generally not helpful for treatment decisions 1
- Endometrial biopsy: NOT cost-effective or necessary in women without abnormal bleeding 3
Common Pitfalls to Avoid
- Over-medicalization: Do not subject women to unnecessary screening procedures that may inhibit access to HRT 3
- Routine endometrial monitoring: It is NOT necessary to routinely monitor endometrial thickness while using HRT 1
- Serum hormone monitoring: Hormone levels are generally not helpful in making treatment decisions 1
- Delaying treatment for extensive testing: History and physical examination with blood pressure measurement are sufficient to determine if contraindications exist 3
Route Selection Based on Risk Factors
Transdermal estradiol is preferred for:
- BMI >30 kg/m² 4, 1
- Hypertension 4
- Migraine with aura 4
- History of VTE (after hematology consultation) 4, 1
- Increased VTE risk (transdermal has similar risk to baseline population, while oral increases VTE risk especially in first year) 1
Combined estrogen-progestogen required for:
Follow-Up Monitoring Schedule
- 3-month review: Confirm acceptability, efficacy, and adjust if needed
- Annual clinical examination: Including gynecologic exam, breast palpation, weight, and blood pressure measurement 4
- Investigations only if prompted by specific symptoms (e.g., unexpected bleeding) 1, 2
- Cardiovascular risk factor evaluation at each visit 1
The evidence strongly supports that extensive pre-treatment testing beyond history, physical examination, blood pressure, and breast screening is not cost-effective and creates unnecessary barriers to appropriate HRT use 3.